再発性および難治性の侵襲性非ホジキンリンパ腫に対する救済化学療法（R-ESHAP）の安全性および有効性に関する研究

基本情報

NCT ID

NCT00367497

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

5

治験依頼者名

Keio University

概要

Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes refractory to chemotherapy. Various second or third line chemotherapies, which are called salvage chemotherapy, were developed without promising results. Improvement in efficacy by adding relatively new agent, rituximab, to chemotherapy is now widely accepted in non-Hodgkin's lymphoma. This study will test the safety and efficacy of adding rituximab to existing salvage chemotherapy, ESHAP (R-ESHAP). Our aim is also to proceed to high-dose chemotherapy with autologous hematopoietic stem cell transplantation after successful R-ESHAP therapy.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)